Trade Names:Neosporin- Ophthalmic Ointment 10,000 units/g polymyxin B sulfate, 3.5 mg/g neomycin, and 400 units/g bacitracin zincNeosporin Ointment (Canada)
Interferes with bacterial cell wall synthesis by inhibiting regeneration of phospholipid receptors involved with peptidoglycan synthesis.Neomycin
Inhibits protein synthesis by binding to ribosomal RNA, causing bacterial genetic code misreading.Polymyxin B
Interacts with phospholipid components of bacterial cell membrane, increasing cell wall permeability.
Treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists; inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is expected to obtain a diminution in edema and inflammation; chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies; when risk of infection is high or where there is expectation that potentially dangerous numbers of bacteria will be present in the eye.
Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the corneal and conjunctiva; mycobacterial eye infections; fungal diseases of the ocular structures; uncomplicated removal of a corneal foreign body; hypersensitivity to any component of the product.
Ophthalmic Instill 1 or 2 gtt in the eye every 3 or 4 h or more frequently as required. Acute infections may require administration every 30 min, with decreasing frequency as the infection is brought under control.Lids
Ophthalmic Instill 1 or 2 gtt in the eye every 3 to 4 h, close the eye, and rub the excess on the lids and lid margins.
Store below 77°F. Keep tube tightly capped. Protect from freezing.
None well documented.
None well documented.
Elevated IOP with possible development of glaucoma; optic nerve damage; posterior subcapsular cataract formation; delayed wound healing; secondary infection; fungal infection; acute anterior uveitis and perforation of the globe.
Category C .
Excreted in breast milk.
Safety and efficacy not established.
Prolonged use may result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Allergic cross-sensitivity to kanamycin, paromomycin, streptomycin, and possibly gentamicin may occur.
Prolonged use may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.
Secondary bacterial ocular infection following suppression of host responses may occur.
Copyright © 2009 Wolters Kluwer Health.